The Novavax vaccine has seen less fanfare as it moves through the regulatory process. But it could play an important role in the pandemic.
The two-dose Novavax contains the protein spike of the virus that causes COVID-19 and a Matrix-M adjuvant to boost the immune system's response. Protein-based vaccines are already widely used for other ailments, including hepatitis B and whooping cough.
The FDA gave emergency use authorization to Novavax, the fourth inoculation against COVID-19, as public health officials say the protein-based shots could play a key role as the pandemic lingers. Above, a health worker prepares a Novavax dose as the Dutch Health Service Organization begins its program on March 21, 2022, in The Hague, Netherlands.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
US regulators OK new COVID-19 shot option from NovavaxNovavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S.
続きを読む »
US regulators OK new COVID-19 shot option from NovavaxNovavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S.
続きを読む »
Novavax COVID-19 vaccine: FDA authorizes fourth shot for adultsNovavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S. -- and one that’s already available in Europe and multiple other countries.
続きを読む »
US regulators OK new COVID-19 shot option from NovavaxNovavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S.
続きを読む »
US regulators OK new COVID-19 shot option from NovavaxThe U.S. is getting another COVID-19 vaccine choice
続きを読む »